Spyglass Pharma

spyglasspharma.com

Spy Glass Pharma™ is a privately-held ophthalmic biotechnology company focused on developing a controlled release drug delivery platform for glaucoma treatment. Their innovative technology allows for the sustained delivery of bimatoprost over multiple years, addressing the critical issue of patient non-adherence to glaucoma medications. The platform is designed to be implanted during routine cataract surgery, making it a versatile solution for millions of glaucoma patients. With a strong leadership team and ongoing clinical trials, Spy Glass Pharma is positioned to make a significant impact in the ophthalmic market.